Prognostic Value of KRAS/TP53 Status in NSCLC Treatment
Author Information
Author(s): de Jager Vincent D. MD, van Kempen Léon C. PhD, Cajiao Garcia Betzabel N. MSc, Hiltermann T. Jeroen N. MD, PhD, van der Wekken Anthonie J. MD, PhD, Schuuring Ed PhD, Willems Stefan M. MD, PhD
Primary Institution: University of Groningen, University Medical Center Groningen
Hypothesis
What is the prognostic value of KRAS/TP53 mutation status for overall survival in patients with nonsquamous NSCLC treated with immunotherapy?
Conclusion
The presence of KRAS and TP53 mutations is associated with longer overall survival in patients treated with pembrolizumab or chemoimmunotherapy.
Supporting Evidence
- Mutations in KRAS and TP53 occurred in 48.8% and 58.4% of patients, respectively.
- Median overall survival differed significantly between KRAS/TP53 mutational subgroups.
- Patients with mutated TP53 had longer median overall survival compared to those with wildtype KRAS.
- Multivariable analysis showed KRAS/TP53 mutation status was not significantly associated with overall survival.
Takeaway
This study found that patients with certain gene mutations lived longer when treated with specific cancer therapies.
Methodology
Clinical data from the Netherlands Cancer Registry were analyzed for patients diagnosed with metastatic nonsquamous NSCLC in 2019, focusing on KRAS and TP53 mutation status.
Potential Biases
Potential bias from incomplete detection of mutations and selection of only patients tested for mutations.
Limitations
The study may have selection bias due to incomplete mutation detection and the geographic limitation of a single-year cohort.
Participant Demographics
Median age was 65 years, with 51% male participants.
Statistical Information
P-Value
0.007
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website